The effect of left atrial appendage closure on heart failure
biomarkers: A PRAGUE-17 trial subanalysis

J 2021

The effect of left atrial appendage closure on heart failure biomarkers: A PRAGUE-17 trial subanalysis

HERMAN, Dalibor, Pavel OSMANCIK, Petr NEUZIL, Pavel HALA, Veronika LEKESOVA et. al.

Základní údaje

Originální název

The effect of left atrial appendage closure on heart failure biomarkers: A PRAGUE-17 trial subanalysis

Autoři

HERMAN, Dalibor (203 Česká republika), Pavel OSMANCIK (203 Česká republika, garant), Petr NEUZIL (203 Česká republika), Pavel HALA (203 Česká republika), Veronika LEKESOVA, Klára BENEŠOVÁ (203 Česká republika, domácí), Marek HOZMAN (203 Česká republika), Jiří JARKOVSKÝ (203 Česká republika, domácí), Martina NOVÁČKOVÁ (203 Česká republika, domácí), Petr WIDIMSKY (203 Česká republika) a V. Y. REDDY

Vydání

JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, HOBOKEN, WILEY, 2021, 1045-3873

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.942

Kód RIV

RIV/00216224:14110/21:00123114

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1111/jce.15206

UT WoS

000688562000001

Klíčová slova anglicky

atrial natriuretic peptide; biomarkers; brain natriuretic peptide; left atrial appendage; left atrial appendage closure

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 6. 12. 2021 09:11, Mgr. Tereza Miškechová

Anotace

V originále

Introduction The randomized PRAGUE-17 trial demonstrated noninferiority of left atrial appendage closure (LAAC) to non-vitamin K anticoagulants (NOACs) for the prevention of major cardiovascular or cerebrovascular events. However, the left atrial appendage is an important source of natriuretic peptides and plays a role in left atrial reservoir function. Changes of heart failure (HF) biomarkers after LAAC compared to NOAC has not been studied. The aim of the study was to compare the changes in concentrations of HF biomarkers between LAAC and NOAC patients. Methods Of 402 patients randomized in the PRAGUE-17 trial, biomarkers were analyzed in 144 patients (73 in the NOAC and 71 in the LAAC group). Both groups had similar baseline characteristics. Serum concentration of NT-proBNP, NT-proANP, Galectin-3, and GDF-15 were measured at baseline (before the procedure in the LAAC group), at the 6-month (and at 24-month for NT-proBNP) follow-up timepoint. Results There were no significant differences in baseline, 6 month, and delta (delta = baseline - 6 month) concentrations of NT-proANP between the groups (NOAC: baseline 2.6 [0.5; 4.9], 6-month 3.1 [1.8; 4.8], p = .068; LAAC: baseline 3.3 [1.1; 4.6], 6-month 2.6 [0.9; 5.3], p = .51; p value for delta in concentrations between groups = 0.42). Similarly, there were no significant differences in baseline, 6, 24 months, and delta concentrations of NT-proBNP between the groups (NOAC: baseline 461.0 [113.5; 1342.0], 6 month 440.0 [120.5; 1291.5], 24 month 798 [274; 2236], p = .39; LAAC: baseline 421.0 [100.0; 1320.0], 6 month 601.0 [145.0; 1230.0], 24 month 855 [410; 1367], p = .28; p value for delta in concentrations between groups = 0.73 at 6 months, and 0.58 at 24 months). Finally, no significant differences were present in baseline, 6 month, and delta concentrations of Galectin-3 and GDF-15 between the two groups. Conclusion LAAC did not significantly influence the levels of HF biomarkers 6 months after the procedure.

Citovat

HERMAN, Dalibor, Pavel OSMANCIK, Petr NEUZIL, Pavel HALA, Veronika LEKESOVA, Klára BENEŠOVÁ, Marek HOZMAN, Jiří JARKOVSKÝ, Martina NOVÁČKOVÁ, Petr WIDIMSKY a V. Y. REDDY. The effect of left atrial appendage closure on heart failure biomarkers: A PRAGUE-17 trial subanalysis. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY. HOBOKEN: WILEY, 2021, roč. 32, č. 10, s. 2645-2654. ISSN 1045-3873. Dostupné z: https://dx.doi.org/10.1111/jce.15206.

@article{1807762,
   author = {Herman, Dalibor and Osmancik, Pavel and Neuzil, Petr and Hala, Pavel and Lekesova, Veronika and Benešová, Klára and Hozman, Marek and Jarkovský, Jiří and Nováčková, Martina and Widimsky, Petr and Reddy, V. Y.},
   article_location = {HOBOKEN},
   article_number = {10},
   doi = {http://dx.doi.org/10.1111/jce.15206},
   keywords = {atrial natriuretic peptide; biomarkers; brain natriuretic peptide; left atrial appendage; left atrial appendage closure},
   language = {eng},
   issn = {1045-3873},
   journal = {JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY},
   title = {The effect of left atrial appendage closure on heart failure biomarkers: A PRAGUE-17 trial subanalysis},
   url = {https://onlinelibrary.wiley.com/doi/10.1111/jce.15206},
   volume = {32},
   year = {2021}
}

TY  - JOUR
ID  - 1807762
AU  - Herman, Dalibor - Osmancik, Pavel - Neuzil, Petr - Hala, Pavel - Lekesova, Veronika - Benešová, Klára - Hozman, Marek - Jarkovský, Jiří - Nováčková, Martina - Widimsky, Petr - Reddy, V. Y.
PY  - 2021
TI  - The effect of left atrial appendage closure on heart failure biomarkers: A PRAGUE-17 trial subanalysis
JF  - JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY
VL  - 32
IS  - 10
SP  - 2645-2654
EP  - 2645-2654
PB  - WILEY
SN  - 10453873
KW  - atrial natriuretic peptide
KW  - biomarkers
KW  - brain natriuretic peptide
KW  - left atrial appendage
KW  - left atrial appendage closure
UR  - https://onlinelibrary.wiley.com/doi/10.1111/jce.15206
N2  - Introduction The randomized PRAGUE-17 trial demonstrated noninferiority of left atrial appendage closure (LAAC) to non-vitamin K anticoagulants (NOACs) for the prevention of major cardiovascular or cerebrovascular events. However, the left atrial appendage is an important source of natriuretic peptides and plays a role in left atrial reservoir function. Changes of heart failure (HF) biomarkers after LAAC compared to NOAC has not been studied. The aim of the study was to compare the changes in concentrations of HF biomarkers between LAAC and NOAC patients. Methods Of 402 patients randomized in the PRAGUE-17 trial, biomarkers were analyzed in 144 patients (73 in the NOAC and 71 in the LAAC group). Both groups had similar baseline characteristics. Serum concentration of NT-proBNP, NT-proANP, Galectin-3, and GDF-15 were measured at baseline (before the procedure in the LAAC group), at the 6-month (and at 24-month for NT-proBNP) follow-up timepoint. Results There were no significant differences in baseline, 6 month, and delta (delta = baseline - 6 month) concentrations of NT-proANP between the groups (NOAC: baseline 2.6 [0.5; 4.9], 6-month 3.1 [1.8; 4.8], p = .068; LAAC: baseline 3.3 [1.1; 4.6], 6-month 2.6 [0.9; 5.3], p = .51; p value for delta in concentrations between groups = 0.42). Similarly, there were no significant differences in baseline, 6, 24 months, and delta concentrations of NT-proBNP between the groups (NOAC: baseline 461.0 [113.5; 1342.0], 6 month 440.0 [120.5; 1291.5], 24 month 798 [274; 2236], p = .39; LAAC: baseline 421.0 [100.0; 1320.0], 6 month 601.0 [145.0; 1230.0], 24 month 855 [410; 1367], p = .28; p value for delta in concentrations between groups = 0.73 at 6 months, and 0.58 at 24 months). Finally, no significant differences were present in baseline, 6 month, and delta concentrations of Galectin-3 and GDF-15 between the two groups. Conclusion LAAC did not significantly influence the levels of HF biomarkers 6 months after the procedure.
ER  -

HERMAN, Dalibor, Pavel OSMANCIK, Petr NEUZIL, Pavel HALA, Veronika LEKESOVA, Klára BENEŠOVÁ, Marek HOZMAN, Jiří JARKOVSKÝ, Martina NOVÁČKOVÁ, Petr WIDIMSKY a V. Y. REDDY. The effect of left atrial appendage closure on heart failure biomarkers: A PRAGUE-17 trial subanalysis. \textit{JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY}. HOBOKEN: WILEY, 2021, roč.~32, č.~10, s.~2645-2654. ISSN~1045-3873. Dostupné z: https://dx.doi.org/10.1111/jce.15206.

Podrobný výpis o publikaci